<div id="readability-page-1"><div><p>General Proximity announced a strategic multi-target collaboration with Daiichi Sankyo through its Daiichi Sankyo Research Institute in Boston to apply General Proximity's proprietary OmniTAC discovery platform to oncology programs of interest to Daiichi Sankyo. Induced proximity medicines enable the precise and selective modification of disease-driving proteins, creating therapeutic opportunities for traditionally undruggable targets. The approach uses small molecules to bring two proteins into close physical proximity and subsequently induce a desired therapeutic effect.</p><p>The OmniTAC platform allows unbiased screening for effector proteins capable of modulating disease-relevant targets, offering a powerful and differentiated approach to drug discovery. Under the terms of the collaboration, General Proximity will leverage OmniTAC to discover and characterize novel effector-target pairs with the potential to generate first-in-class therapeutic candidates. In parallel with this collaboration, General Prox proximity will continue to expand the reach of its OmniTAC platform by leveraging the precise control of proximity to address undruggable targets across multiple disease areas.</p><p>In addition to oncology, the company is advancing programs in cardiometabolic disease, neurodegeneration, and longevity, underscoring its commitment to translating breakthrough science into transformative therapies for patients worldwide.</p></div></div>

第一三共株式会社(ADR)

<p>General Proximity 宣布与第一三共株式会社（ADR）建立战略合作关系，利用其 OmniTAC 发现平台进行肿瘤学项目。此次合作旨在开发诱导接近药物，针对致病蛋白，创造以前无法药物化的靶点的治疗机会。该合作将专注于发现潜在的首创疗法的新型效应器 - 靶点对，同时还将扩展 OmniTAC 在心代谢疾病、神经退行性疾病和长寿领域的应用</p>

General Proximity 宣布与第一三共株式会社 (ADR) 达成战略性多目标合作